Show simple item record

dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorBuğdaycı Basal, Fatma
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorErman, Mustafa
dc.contributor.authorYumuk, Fulden
dc.contributor.authorÇay Şenler, Filiz
dc.contributor.authorÇakar, Burcu
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorÖztürk, Akın
dc.contributor.authorCoşkun, Hasan Şenol
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorKaraağaç, Mehmet Onur
dc.contributor.authorSakalar, Teoman
dc.contributor.authorEralp, Yeşim
dc.contributor.authorKorkmaz, Taner
dc.date.accessioned2019-12-24T12:15:18Z
dc.date.available2019-12-24T12:15:18Z
dc.date.issued2019en_US
dc.identifier.citationKılıçkap, S., Buğdaycı Basal, F., Demirkazık, A., Gürsoy, P., Demirci, U., Erman, M. ... Korkmaz, T. (2019). Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?44th Congress of the European-Society-for-Medical-Oncology (ESMO) içinde (637-637. ss.). Barcelona, Spain, September 27-October 01, 2019.en_US
dc.identifier.issn1569-8041
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4651
dc.descriptionConference Conference: 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: SEP 27-OCT 01, 2019 Sponsor(s):European Soc Med Oncol; Japanese Soc Med Oncolen_US
dc.description.abstractBackground: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who have Ple-I/E. Methods: In this multicenter study, patients with ALKþ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALKþpatients with NSCLC. Results: Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼0.541). The rate of smokers was 43.4% (n¼157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALKþpatients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼0.008; 19.1% vs 4.8%, p¼0.002; 20.6% vs 8.9%, p¼0.003). The median PFS was longer in ALKþ patients who have Ple-I/E 18.7 vs 10.6 months, p¼0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALKþpatients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼0.051). The 1-, 2- and 3- year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions: Brain, liver and bone metastases are lower in ALKþpatients with Ple-I/E. Presentation with Ple-I/E in patients with ALKþ NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.en_US
dc.description.sponsorshipEuropean Society for Medical Oncologyen_US
dc.description.sponsorshipJapanese Society of Medical Oncologyen_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectALK-Positiveen_US
dc.subjectEffusionen_US
dc.subjectPrognostic Significanceen_US
dc.titleIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?en_US
dc.typeconferenceObjecten_US
dc.relation.ispartof44th Congress of the European-Society-for-Medical-Oncology (ESMO)en_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume30en_US
dc.identifier.issueSupplement: 5en_US
dc.identifier.startpage637en_US
dc.identifier.endpage637en_US
dc.relation.ec0923-7534
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.wosqualityQ1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record